[A22-40] Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 01.07.2022
Project no.:
A22-40
Commission:
Commission awarded on 01.04.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Adults with multiple myeloma who have received at least one prior therapy
Result of dossier assessment:
- Patients with ISS stage II or III: proof of considerable added benefit
- Patients with ISS stage I: proof of minor added benefit
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.